Novartis (NVS) news

Novartis India approves raising upto 9B rupees via rights issue

Novartis India Limited, now rebranded as Evonile Pharma Limited, has announced plans to raise up to 9 billion rupees through a rights issue. This move follows a series of strategic developments, including the company’s recent corporate rebranding and the acquisition of a majority stake by…

Isomorphic Labs in funding talks for at least $40 billion value

Isomorphic Labs, an artificial intelligence-driven drug discovery company, has attracted significant investor interest, with recent reports suggesting the firm is in funding discussions that could value the company at $40 billion or more. This potential valuation would represent a substantial…

Novartis AG - Rhapsido safety profile in SD consistent with CSU; no routine lab monitoring required

Novartis AG has reported that the safety profile of Rhapsido in patients with chronic spontaneous urticaria (CSU) is consistent with its known characteristics. The company emphasized that routine laboratory monitoring is not required for patients receiving the treatment, based on findings from its…

Novartis AG - 29.3% of rhapsido patients achieve complete response from HIVES at week 12 vs 14.0% placebo

Novartis AG - Rhapsido only approved treatment for both CSU and SD when antihistamines fail

Novartis AG has positioned Rhapsido® (remibrutinib) as the only treatment approved for both chronic spontaneous urticaria (CSU) and solar urticaria (SD) in patients who have not responded adequately to antihistamines. This distinction highlights the drug’s unique regulatory status and potential…